Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
54.62
+0.21 (0.39%)
Nov 20, 2024, 4:00 PM EST - Market closed
Agios Pharmaceuticals Revenue
Agios Pharmaceuticals had revenue of $8.96M in the quarter ending September 30, 2024, with 21.15% growth. This brings the company's revenue in the last twelve months to $32.87M, up 36.79% year-over-year. In the year 2023, Agios Pharmaceuticals had annual revenue of $26.82M with 88.36% growth.
Revenue (ttm)
$32.87M
Revenue Growth
+36.79%
P/S Ratio
93.91
Revenue / Employee
$85,158
Employees
386
Market Cap
3.11B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BrightSpring Health Services | 10.59B |
Bausch Health Companies | 9.47B |
Amedisys | 2.32B |
PTC Therapeutics | 900.66M |
Inari Medical | 574.50M |
Merus | 35.93M |
AGIO News
- 15 days ago - Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - GlobeNewsWire
- 20 days ago - Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Agios Reports Business Highlights and Third Quarter 2024 Financial Results - GlobeNewsWire
- 5 weeks ago - Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024 - GlobeNewsWire
- 2 months ago - Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS) - GlobeNewsWire
- 2 months ago - Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 - GlobeNewsWire
- 3 months ago - Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment - Seeking Alpha
- 3 months ago - Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib - GlobeNewsWire